Parabilis Medicines Inc. (PBLS)
PBLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PBLS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001657677 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $521.2M cash; operating cash flow -$36.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 125,257,825 (2026-11-09). | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-06-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $441.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.1M | -$44.5M | -$41.1M | $521.2M | $3.3M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $148K | -$52.5M | Not filed | $1.1B | $11.4M | Needs four quarters | 10-Q 2026-08-13 |
| Q3 2026 2026-03-31 | Not filed | -$45.3M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | $0 | -$33.5M | -$31.5M | $57.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2025-06-30 | $0 | -$34.8M | Not filed | $80.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q3 2026 2025-03-31 | Not filed | -$38.3M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-06-10 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 65 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | +5.9% |
| 3 months | -20.3% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -31.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier